会员体验
专利管家（专利管理）
工作空间（专利管理）
风险监控（情报监控）
数据分析（专利分析）
侵权分析（诉讼无效）
联系我们
交流群
官方交流：
QQ群： 891211   
微信请扫码    >>>
现在联系顾问~
下载
著录项
PDF全文
热词
    • 7. 发明公开
      KR1020090014856A 카스파제-7 절단에서 유래하는 세포사멸과 관련된폴리뉴클레오티드 서열, 세포사멸의 억제, 유도 인자 및이의 스크리닝 방법 失效
    • 카스파제-7 절단에서 유래하는 세포사멸과 관련된폴리뉴클레오티드 서열, 세포사멸의 억제, 유도 인자 및이의 스크리닝 방법
    • 与CASPASE-7，抑制剂或疫苗诱导物诱导的病毒相关的多核苷酸序列及其筛选方法
    • KR1020090014856A
    • 2009-02-11
    • KR1020070079155
    • 2007-08-07
    • 한국생명공학연구원
    • 김수정 , 염영일 , 김남순 , 유향숙 , 박경미 , 강은주 , 전여진 , 김나영
    • C12N15/12 , C12N15/09
    • A polynucleotide sequence associated with apoptosis which is induced from cleavage of caspase-7 is provided to treat diseases caused by apoptosis including cancer, autoimmune disease, virus infection, endocrine system disease and chronic hyperplasia. The purified or isolated polynucleotide sequence associated with apoptosis induced from cleavage of caspase-7 comprises one selected from (a) the polynucleotide sequence of SEQ ID NO:1, (b) the polynucleotide sequence having more than 70% homology to the DNA of (a), (c) the polynucleotide sequence which hybridizes with the polynucleotide sequence of (a) or (b) under stringent condition, and (d) the polynucleotide sequence or RNA sequence complementary with the sequence of (a), (b) or (c). A screening method of the inhibitor or inducer of apoptosis comprises the steps of: culturing a cell expressing the gene in the presence of a candidate drug; culturing the cell expressing the gene in the absence of the candidate drug; and comparing the results of cultivation in the presence and absence of the candidate drug.
    • 提供与由胱天蛋白酶-7的切割诱导的细胞凋亡相关的多核苷酸序列，以治疗由凋亡引起的疾病，包括癌症，自身免疫疾病，病毒感染，内分泌系统疾病和慢性增生。 与由胱天蛋白酶-7的切割诱导的细胞凋亡相关的纯化或分离的多核苷酸序列包含选自（a）SEQ ID NO：1的多核苷酸序列，（b）多核苷酸序列与（ a），（c）在严格条件下与（a）或（b）的多核苷酸序列杂交的多核苷酸序列，和（d）与（a），（b）或（b）的序列互补的多核苷酸序列或RNA序列 （C）。 抑制剂或诱导剂的筛选方法包括以下步骤：在候选药物的存在下培养表达该基因的细胞; 在不存在候选药物的情况下培养表达该基因的细胞; 并比较候选药物存在和不存在时的培养结果。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Espacenet 法律信息 同族专利 专利引用
    • 8. 发明公开
      KR1020090014855A 카스파제-7 절단에서 유래하는 세포사멸과 관련된폴리뉴클레오티드 서열, 세포사멸의 억제, 유도 인자 및이의 스크리닝 방법 失效
    • 카스파제-7 절단에서 유래하는 세포사멸과 관련된폴리뉴클레오티드 서열, 세포사멸의 억제, 유도 인자 및이의 스크리닝 방법
    • 与CASPASE-7，抑制剂或疫苗诱导物诱导的病毒相关的多核苷酸序列及其筛选方法
    • KR1020090014855A
    • 2009-02-11
    • KR1020070079154
    • 2007-08-07
    • 한국생명공학연구원
    • 김수정 , 염영일 , 김남순 , 유향숙 , 박경미 , 강은주 , 전여진 , 김나영
    • C12N15/12 , C12N15/11 , C12N15/09
    • An inducer of apoptosis comprising the polynucleotide sequence associated with apoptosis induced from cleavage of caspase-7 is provided to treat diseases including cancer, autoimmune disease, virus infection, endocrine system disease, chronic hyperplasia, post-angioplasty restenosis, post-operational recurrence of the carcinomas and rejection of transplanted organs. The inducer of apoptosis comprises the polynucleotide sequence associated with apoptosis induced from cleavage of caspase-7, which comprises one selected from (a) the polynucleotide sequence of SEQ ID NO:1, (b) the polynucleotide sequence having more than 70% homology to the DNA of (a), (c) the polynucleotide sequence which hybridizes with the polynucleotide sequence of (a) or (b) under stringent condition, and (d) the polynucleotide sequence or RNA sequence complementary with the sequence of (a), (b) or (c).
    • 提供了包含与半胱天冬酶-7的切割诱导的凋亡相关的多核苷酸序列的凋亡诱导剂，用于治疗包括癌症，自身免疫疾病，病毒感染，内分泌系统疾病，慢性增生，血管成形术后再狭窄，术后复发的疾病 移植器官的癌和排斥。 凋亡诱导物包含与由胱天蛋白酶-7切割诱导的凋亡相关的多核苷酸序列，其包含选自（a）SEQ ID NO：1的多核苷酸序列，（b）与SEQ ID NO：1的多核苷酸序列具有超过70％同源性的多核苷酸序列 （a）的DNA，（c）在严格条件下与（a）或（b）的多核苷酸序列杂交的多核苷酸序列，和（d）与（a），（b）的序列互补的多核苷酸序列或RNA序列， （b）或（c）。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Espacenet 法律信息 同族专利 专利引用
    • 9. 发明公开
      KR1020080047104A 형질전환 동물의 유즙으로부터 재조합 단백질을 정제하기위한 전처리 방법 失效
    • 형질전환 동물의 유즙으로부터 재조합 단백질을 정제하기위한 전처리 방법
    • 用于从转基因动物乳清除重组蛋白的预处理方法
    • KR1020080047104A
    • 2008-05-28
    • KR1020060117027
    • 2006-11-24
    • 한국생명공학연구원
    • 정봉현 , 이은교 , 정준기 , 이승희 , 박경미 , 백정은
    • C07K1/14 , C07K1/30
    • A method for pre-treating milk of a transgenic animal is provided to improve the purification efficiency of recombinant proteins from the transgenic animal milk by shortening the purification time into about 4 hours and showing the recovery rate of at least 80%, thereby being used for mass-producing the recombinant proteins. A method for pre-treating milk of a transgenic animal before purification of recombinant proteins from the milk of the transgenic animal in case of precipitation of the recombinant protein not being easy comprises the steps of: (a) centrifuging the transgenic animal milk at a temperature of 4-37 deg.C with 4,000-12,000 rpm for 10-40 minutes to recover supernatant therefrom; (b) adding a first precipitating agent to the supernatant to precipitate impurities firstly; (c) adding a transition metal salt to the product obtained from the step(b) to precipitate impurities secondly; and (d) recovering the supernatant obtained from the step(c) and subjecting it to a precise filtration to remove impurities therefrom, wherein the steps(b) and (c) may reverse the order or performed at the same time. A method for pre-treating milk of a transgenic animal before purification of recombinant proteins from the milk of the transgenic animal in case of precipitation of the recombinant protein being easy comprises the steps of: (a) centrifuging the transgenic animal milk at a temperature of 4-37 deg.C with 4,000-12,000 rpm for 10-40 minutes to remove fat therefrom and recovering supernatant therefrom; (b) adding a first precipitating agent to the supernatant to precipitate recombinant proteins firstly; (c) adding a transition metal salt to the product obtained from the step(b) to precipitate the recombinant proteins secondly; and (d) after dissolving the precipitated recombinant protein in a buffer solution, subjecting the solution to a precise filtration to remove impurities therefrom, wherein the steps(b) and (c) may reverse the order or performed at the same time. Further, the transition metal salt is salt comprising a transition metal selected from a group consisting of Mn, Fe, Co, Ni, Cu and Zn.
    • 提供了一种用于转基因动物的牛奶预处理的方法，以通过将纯化时间缩短至约4小时并显示至少80％的回收率来改善来自转基因动物奶的重组蛋白的纯化效率，从而用于 大量生产重组蛋白。 在沉淀重组蛋白质不容易的情况下，从转基因动物的乳中纯化重组蛋白质之前对转基因动物的牛奶进行预处理的方法包括以下步骤：（a）在温度下离心转基因动物奶 4-40℃，4,000-12,000rpm，10-40分钟，回收上清液; （b）首先向上清液中加入第一沉淀剂以沉淀杂质; （c）向步骤（b）得到的产物中加入过渡金属盐，以沉淀杂质二次; 和（d）回收由步骤（c）获得的上清液并对其进行精确过滤以除去杂质，其中步骤（b）和（c）可以颠倒或同时进行。 在重组蛋白质沉淀容易的情况下从转基因动物的乳中纯化重组蛋白质之前对转基因动物的牛奶进行预处理的方法包括以下步骤：（a）在转基因动物奶的温度 4-7℃，4,000-12,000rpm 10-40分钟，以除去脂肪，并从中回收上清液; （b）首先向上清液中加入第一沉淀剂沉淀重组蛋白质; （c）向由步骤（b）获得的产物中加入过渡金属盐以沉淀重组蛋白质; 和（d）将沉淀的重组蛋白质溶解在缓冲溶液中后，对溶液进行精确过滤以除去杂质，其中步骤（b）和（c）可以颠倒或同时进行。 此外，过渡金属盐是包含选自Mn，Fe，Co，Ni，Cu和Zn中的过渡金属的盐。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Espacenet 法律信息 同族专利 专利引用
每页展示10个专利
每页展示10个专利
每页展示20个专利
每页展示50个专利
每页展示100个专利

IPRDB

最新中国发明专利 最新美国发明专利 技术领域 专利库 专利分类库 国际专利分类库

热门服务

会员版试用 API 数据接口 找代理 知嘟嘟专利交易 排行榜 大学排行榜 专利百科

关于我们

平台介绍 战略合作 网站地图

友情链接

知嘟嘟专利交易 国家知识产权局 中国商标网

联系方式


©2019-2023 上海吉码数字技术有限公司 版权所有，并保留所有权利 沪ICP备20016256号-6 沪公网安备31011702005475号